iPad games effective against amblyopia

Article

A home-based treatment of amblyopia that incorporated an iPad quickly resulted in improved visual acuity (VA) in the children in whom it was tested, and VA remained stable for at least 3 months after the treatment ended, according to research published online.

A home-based treatment of amblyopia that incorporated an iPad quickly resulted in improved visual acuity (VA) in the children in whom it was tested, and VA remained stable for at least 3 months after the treatment ended, according to research published online by Eye.

The binocular treatment is promising, according to the Texas researchers, because monocular treatment does not always lead to 6/6 vision, and patients often see the return of amblyopia. "In addition to the efficacy and durability of this binocular iPad treatment, it is fun and engaging and results in better compliance than patching, at the same time imposes little risk for adverse psychosocial effects," the authors say.

In the study, children aged 4 to 12 years played either sham games or binocular games on an iPad for 4 hours a week for 4 weeks while wearing anaglyphic glasses. Children assigned to binocular games could choose to play for an additional 4 weeks.

The sham group had 25 children, and the binocular group had 50. Approximately half of the children in each group also wore patching at a different time of day than when they were playing games.

Researchers measured best-corrected VA, suppression and stereoacuity at baseline, at the 4- and 8-week outcome visits, and 3 months after treatment ended. They found that, in the binocular group, mean VA went from 0.47±0.03 logMAR at baseline to 0.39±0.03 logMAR at 4 weeks. No significant change was seen in the sham group.

Patching did not change the effect of the binocular games on VA in the children, nor did an additional 4 weeks of treatment in those children playing the binocular games result in greater improvement in VA. Median stereoacuity remained unchanged in both groups.

For full details of the study click

here

.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.